CTX combined with Glucocorticoids

Phase 3Small molecule

CTX combined with Glucocorticoids is one of 37 small molecule programs targeting Membranous Nephropathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Membranous NephropathyActive, not recruiting

Membranous NephropathyPhase 3

Active, not recruiting

Competition

Competitive Landscape

75 competitors in Membranous Nephropathy

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

16 2

Neoral

Novartis

Phase 3

4 3

Gazyva

Roche

Phase 3

3 4

Medrol

Pfizer

Phase 3

2 5

Prograf

VVeloxis Pharmaceuticals

Phase 3

6 6

Brukinsa

BBeOne Medicines

Phase 3

1 7

Felzartamab

Biogen

Phase 3

1 8

Tylenol

Benadryl

Povetacicept

Vertex Pharmaceuticals

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Recruiting

Membranous Nephropathy

NCT06781944

Clinical

Trials by Indication[1]

Membranous Nephropathy1 trial

OBINOTUZUMAB Versus Cyclophosphamide + Glucocorticoids in Primary Membranous Nephropathy(Blossom Study)

Recruiting·HHuashan Hospital·Phase 3·NCT06781944·144 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CTX combined with Glucocorticoids. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CTX combined with Glucocorticoids compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CTX combined with Glucocorticoids. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Huashan Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHuashan Hospital

CTX combined with Glucocorticoids

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Membranous Nephropathy1 trial

References

Drug Info

Quick Facts

Related News